Evidence map›Paper›PMID 37154745›Full record

ArticleAntimicrobial agents and chemotherapy2023

Amplicon Deep Sequencing Reveals Multiple Genetic Events Lead to Treatment Failure with Atovaquone-Proguanil in Plasmodium falciparum.

Daniel Castañeda-Mogollón, Noah B Toppings, Claire Kamaliddin, Raynell Lang, Susan Kuhn, Dylan R Pillai

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Daniel Castañeda-MogollónCumming School of Medicine, Department of Pathology & Laboratory Medicine, the University of Calgary, Calgary, Alberta, Canada.
Noah B ToppingsCumming School of Medicine, Department of Pathology & Laboratory Medicine, the University of Calgary, Calgary, Alberta, Canada.
Claire KamaliddinCumming School of Medicine, Department of Pathology & Laboratory Medicine, the University of Calgary, Calgary, Alberta, Canada.
Raynell LangCumming School of Medicine, Department of Medicine, the University of Calgary, Calgary, Alberta, Canada.
Susan KuhnCumming School of Medicine, Department of Pediatrics, the University of Calgary, Calgary, Alberta, Canada.
Dylan R PillaiCumming School of Medicine, Department of Pathology & Laboratory Medicine, the University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0001-9518-5551
University of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atovaquone-proguanil (AP) is used as treatment for uncomplicated malaria, and as a chemoprophylactic agent against Plasmodium falciparum. Imported malaria remains one of the top causes of fever in Canadian returning travelers. Twelve sequential whole-blood samples before and after AP treatment failure were obtained from a patient diagnosed with P. falciparum malaria upon their return from Uganda and Sudan. Ultradeep sequencing was performed on the

Indexed as

AntimalarialsMalaria, FalciparumAtovaquoneCanadaDrug CombinationsHigh-Throughput Nucleotide SequencingHumansPlasmodium falciparumProguanilRecurrenceSepharoseTetrahydrofolate DehydrogenaseTreatment FailureAntimalarialsAtovaquoneatovaquone, proguanil drug combinationDrug CombinationsProguanilSepharoseTetrahydrofolate Dehydrogenaseamplicon deep sequencingantimalarial agentscomplexity of infectionde novo mutationDNA sequencinggenomicsmalariaMalaronePlasmodium falciparum

Identifiers

PMID37154745
PMCPMC10269153
OpenAlexW4375859703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.